Gene therapy for moderate Parkinson's disease
Part of Brain & nervous system clinical trials.
This trial tests a gene therapy (AAV2-GDNF) to see if it can slow or improve symptoms of Parkinson's disease. It is for people who have had moderate Parkinson's for 4 to 10 years and still respond to levodopa therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 45 and 75 years old
- You have been diagnosed with Parkinson's disease for 4 to 10 years
- Your Parkinson's symptoms include slowness of movement plus at least one other symptom (stiffness, tremor, or balance problems)
- You have 'off' periods (motor fluctuations) despite medication
- Your Parkinson's medications have been stable for at least 4 weeks
- You respond well to levodopa therapy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment made from your own cells to replace damaged brain cells, aiming to improve movement and reduce symptoms. It's for people who have had Parkinson's for at least 4 years and respond well to levodopa.
This study tests AB-1005, a gene therapy designed to help manage Parkinson's disease symptoms in Japanese adults. The therapy may help reduce motor fluctuations (periods of better and worse symptom control) in people whose symptoms aren't fully controlled by current medications.
This is an observational study, meaning it doesn’t test a new drug—researchers mainly follow people to better understand moderate Parkinson’s disease and who may be good candidates for future cell therapy. If you have moderate symptoms that aren’t well controlled with tablets, this study may help inform better future treatments.
This trial tests a new cell treatment for Parkinson's disease. It involves injecting special cells into the brain to see if they can safely replace damaged cells and improve symptoms. It might help people who have had Parkinson's for several years and still respond well to medication.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
This trial tests an experimental oral drug called GT-02287 for people with early-stage Parkinson's disease. The study aims to see if the drug can slow progression by targeting a protein linked to Parkinson's, and participants must be willing to have genetic testing and a spinal tap to check for that protein marker.
Hear when a new Parkinson Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.